nan
Artificial Intelligence (AI) In Pharmacovigilance Market Forecast Highlighting Growth From $1.78 Billion To $2.22 Billion
The market size for clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutics has experienced significant expansion in recent years. It is projected to increase from $5.64 billion in 2025 to $6.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.8%. Historically, this growth can be attributed to advancements in genome sequencing technologies, the emergence of early gene therapy research programs, increasing funding for rare disease research, the development of viral vector delivery systems, and growing academic research in molecular genetics.
The clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market size is anticipated to experience substantial growth in the next few years. It is projected to expand to $15.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.0%. This growth during the forecast period can be attributed to the broadening scope of personalized medicine and gene-based therapeutics, an increase in regulatory approvals for gene editing therapies, the expansion of clinical trials for oncology and genetic disorders, advancements in in vivo delivery technologies, and rising investment in next-generation genome engineering platforms. Major trends expected in this period include the growing adoption of precision gene correction therapies for rare genetic disorders, an intensified clinical focus on programmable nuclease-based therapeutic platforms, the expansion of personalized regenerative medicine pipelines, the increased use of advanced delivery vectors for targeted gene editing, and the greater integration of high-fidelity gene editing validation and safety screening frameworks.
Download A Free Sample Report For Comprehensive Market Insights:
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Demand Drivers: What Is Fueling Industry Growth?
The growing incidence of genetic and chronic diseases is anticipated to stimulate the expansion of the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market in the coming years. Genetic and chronic diseases refer to health conditions originating from inherited genetic mutations or persistent, long-term health issues such as sickle cell anemia, cystic fibrosis, diabetes, cancer, and cardiovascular diseases. The prevalence of these conditions is increasing, primarily due to aging populations, as older individuals are more susceptible to developing long-term health challenges including cancer, diabetes, cardiovascular diseases, and age-related genetic disorders. Clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutics offer a treatment avenue for genetic and chronic diseases by precisely modifying disease-causing genes to correct mutations and improve long-term patient outcomes for conditions like cancer, diabetes, cystic fibrosis, and sickle cell anemia. For example, in October 2025, the Cystic Fibrosis Trust, a UK-based charity committed to supporting those with cystic fibrosis, reported an increase in cystic fibrosis patient registrations from 11,148 in 2022 and 11,318 in 2023 to 11,381 in 2024, demonstrating continuous year-over-year growth. Thus, the escalating prevalence of genetic and chronic diseases is a key factor propelling the growth of the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market.
Artificial Intelligence (AI) In Pharmacovigilance Market Segmentation: How Is The Market Structured Across Key Categories?
The clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market covered in this report is segmented –
1) By Editing Platform: Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9; Base Editing; Prime Editing; Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12
2) By Disease Target: Sickle Cell Disease And Beta Thalassemia; Cancer Immunotherapy; Hereditary Blindness; Duchenne Muscular Dystrophy; Cardiovascular Disease
3) By Delivery Method: Ex Vivo Cell Engineering; In Vivo; Direct Injection
4) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations; Gene Therapy Startups
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 (CRISPR-Cas9): In Vivo Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Gene Editing Therapeutics; Ex Vivo Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Gene Editing Therapeutics; Viral Vector Based Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Therapeutics; Non Viral Delivery Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 9 Therapeutics
2) By Base Editing: Cytosine Base Editing Therapeutics; Adenine Base Editing Therapeutics; Ribonucleic Acid Guided Base Editing Therapeutics; Precision Base Editing Therapeutics
3) By Prime Editing: Deoxyribonucleic Acid Sequence Correction Prime Editing Therapeutics; Insertion And Deletion Prime Editing Therapeutics; Programmable Prime Editing Therapeutics; High Fidelity Prime Editing Therapeutics
4) By Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 (CRISPR-Cas12): Single Stranded Deoxyribonucleic Acid Targeting Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Therapeutics; Multiplex Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Gene Editing Therapeutics; High Specificity Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Therapeutics; Diagnostic And Therapeutic Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein 12 Platforms
Advancements In CRISPR Gene-Edited Cell Therapies For Transfusion-Dependent Beta Thalassemia
Major companies operating in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market are focusing on developing innovative therapies, such as ex vivo gene-editing therapy to treat inherited genetic disorders and improve long-term patient outcomes. Ex vivo gene-editing therapy is a treatment approach in which a patient’s cells are removed from the body, genetically modified or corrected in a laboratory using gene-editing technologies such as CRISPR/Cas9, and then infused back into the patient to help treat or potentially cure diseases by addressing the underlying genetic defect. For instance, in January 2024, Vertex Pharmaceuticals, a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for CASGEVY (exagamglogene autotemcel [exa-cel]) for the treatment of transfusion-dependent beta thalassemia (TDT) in patients aged 12 years and older. CASGEVY is a one-time CRISPR/Cas9 gene-edited cell therapy designed to address the underlying genetic cause of TDT and reduce dependence on chronic blood transfusions. The approval followed the earlier FDA approval of CASGEVY for sickle cell disease and marked a significant advancement in the application of genome-editing therapeutics for inherited blood disorders. Additionally, Vertex established a network of authorized treatment centers across the U.S. to support the administration of CASGEVY to eligible patients requiring specialized stem cell transplantation procedures.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Key Players And Strategic Industry Positioning
Major companies operating in the clustered regularly interspaced short palindromic repeats (crispr)-based gene editing therapeutic market are Novartis AG; AstraZeneca PLC; Beam Therapeutics Inc.; CRISPR Therapeutics AG; Sana Biotechnology Inc.; Wave Life Sciences Ltd.; Editas Medicine Inc.; EditCo Bio Inc.; Cellectis S.A.; Metagenomi Inc.; Arbor Biotechnologies Inc.; Intellia Therapeutics Inc.; Caribou Biosciences Inc.; Mammoth Biosciences Inc.; Korro Bio Inc.; Scribe Therapeutics Inc.; Allogene Therapeutics Inc.; Prime Medicine Inc.
Access The Complete Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Report:
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Gene Editing Therapeutic Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.